TY - JOUR T1 - Nicotine replacement therapy ‘gift cards’ for hospital inpatients who smoke: a prospective before-and-after controlled pilot evaluation JF - Tobacco Control JO - Tob Control DO - 10.1136/tobaccocontrol-2021-056947 SP - tobaccocontrol-2021-056947 AU - Kerri A Mullen AU - Kathryn L Walker AU - Shireen Noble AU - Gillian Pritchard AU - Aditi Garg AU - Natalie Martin AU - Andrew L Pipe AU - Robert D Reid Y1 - 2021/12/14 UR - http://tobaccocontrol.bmj.com/content/early/2021/12/14/tobaccocontrol-2021-056947.abstract N2 - Introduction A common barrier identified by individuals trying to quit smoking is the cost of cessation pharmacotherapies. The purpose of this evaluation was to: (1) Assess the feasibility of offering nicotine replacement therapy (NRT) ‘gift cards’ to hospitalised smokers for use posthospitalisation; and, (2) Estimate the effect of providing NRT gift cards on 6-month smoking abstinence.Methods A prospective, quasi-experimental, before-and-after controlled cohort design with random sampling was used to compare patients who had received the Ottawa Model for Smoking Cessation (OMSC) intervention (‘control’) with patients who received the OMSC plus a $C300 Quit Card (‘QCI’), which they could use to purchase any brand or form of NRT from any Canadian pharmacy.Results 750 Quit Cards were distributed to the three participating hospitals of which 707 (94.3%) were distributed to patients. Of the cards received by patients, 532 (75.2%) were used to purchase NRT. A total of 272 participants completed evaluation surveys (148 control; 124 QCI).Point prevalence abstinence rates adjusted for misreporting among survey responders were 15.3% higher in the QCI group, compared with controls (44.4% vs 29.1%; OR 1.95, 1.18–3.21; p=0.009). Satisfaction was high among participants in both groups, and among staff delivering the QCI. QCI participants rated the intervention as high in terms of motivation, ease of use and helpfulness.Conclusions The NRT gift card appears to be a feasible and effective smoking cessation tool that removes a primary barrier to the use of evidence-based smoking cessation pharmacotherapies, while motivating both patients and health providers.Data are available upon reasonable request. ER -